Adlbrecht, Christopher
Wurm, Raphael
Depuydt, Pieter
Spapen, Herbert
Lorente, Jose A.
Staudinger, Thomas
Creteur, Jacques
Zauner, Christian
Meier-Hellmann, Andreas
Eller, Philipp
Laenen, Margot Vander
Molnár, Zsolt
Várkonyi, István
Schaaf, Bernhard
Héjja, Mária
Šrámek, Vladimír
Schneider, Hauke
Kanesa-thasan, Niranjan
Eder-Lingelbach, Susanne
Klingler, Anton
Dubischar, Katrin
Wressnigg, Nina
Rello, Jordi
Funding for this research was provided by:
Valneva (Sponsor)
Article History
Received: 11 November 2019
Accepted: 17 February 2020
First Online: 4 March 2020
Ethics approval and consent to participate
: The study was approved by the responsible Ethics Committees and compliant with the current International Conference on Harmonisation/Good Clinical Practice guidelines and in accordance with the principles set forth in the Declaration of Helsinki. Written informed consent was obtained in line with local regulations.
: All co-authors have seen and approved the manuscript, and the manuscript has not been submitted elsewhere.
: SE, KD, and NW are Valneva employees and own stock and share options in Valneva. NK was an employee of GSK during the study and now serves as a consultant to Valneva. JR and CA have received honorary as consultants for the sponsor. CA, RW, PD, HS, JAL, TS, JC, CZ, AMH, PE, MVL, ZM, IV, BS, MH, VŠ, HS and JR received research funding for the trial from the sponsor.